Cibinqo (abrocitinib) — Medica

Initial criteria

• Patient is age ≥ 12 years
• Patient meets ONE of the following: (a) has had a 4-month trial of at least ONE systemic therapy OR (b) has tried at least ONE systemic therapy but was unable to tolerate a 4-month trial
• Examples of systemic therapies include Dupixent (dupilumab), Ebglyss (lebrikizumab-lbkz), Nemluvio (nemolizumab-ilto), Adbry (tralokinumab-ldrm), methotrexate, azathioprine, cyclosporine, and mycophenolate mofetil
• Medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist

Reauthorization criteria

• Patient has already received at least 90 days of therapy with Cibinqo
• Patient experienced a beneficial clinical response defined as improvement from baseline in at least one of: estimated body surface area affected, erythema, induration/papulation/edema, excoriations, lichenification, or decreased requirement for other topical/systemic therapies for atopic dermatitis
• Patient experienced improvement in at least one symptom such as decreased itching

Approval duration

initial: 3 months; reauthorization: 1 year